Pegylated IFN-α 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B

Table 1 Baseline demographic and clinical features of the study population

No	Sex	Age	t (prior lamivudinetherapy) mo	Lamivudine resistancemutation	HBV DNA level	ALT level (times the ULN)
		(yr)			(103 log10 copies/L)
1	M	53	26	L180M + M204V	9.36	1.3
2	M	55	14	L180M + M204I	6.56	6
3	M	63	18	L180M + M204I	7.23	7
4	M	53	25	L180M + M204V	6.68	2.75
5	F	55	19	M204I	6.57	8.5
6	M	63	11	L180M + M204V	6.58	9
7	M	62	10	M204I	8.16	1.3
8	M	47	24	L180M + M204V	7.23	2
9	M	53	18	L180M + M204V	6.86	2.5
10	M	46	16	L180M + M204I	7.98	10
11	M	66	24	L180M + M204V	6.00	1.5
12	F	48	22	L180M + M204I	7.60	3
13	M	54	21	L180M + M204V	9.30	7
14	M	60	41	L180M + M204I	7.51	3.8
15	M	38	29	L180M + M204V	6.26	2.5
16	M	61	22	L180M + M204V	6.57	5
17	M	42	8	M204I	7.43	3.5
18	M	61	25	L180M + M204V	6.98	7
19	M	65	12	L180M + M204I	7.26	5
20	M	54	12	M204I	7.55	2

Table 2 Histological findings in 13 patients with biopsy performed [median (range)]

	Baseline biopsy		End of treatment biopsy
Virological end-treat- ment response	Necroinflammatory	Fibrosis	Necroinflammatory	Fibrosis
	activity		activity
None (n = 8)	3	2	2	3
	(1-3)	(1-3)	(1-4)	(1-4)
Partial (n = 2)	2.5	2.5	2.5	2.5
	(2-3)	(2-3)	(2-3)	(2-3)
Complete (n = 3)	2	2	1	1
	(2-3)	(2-2)	(1-2)	(1-2)